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Since the first commercial cultivation of genetically modified crops in 1994, the rapidly expanding mar-
ket of genetically modified seeds has given rise to a multibillion dollar industry. This fast growth, fueled
by high expectations towards this new commercial technology and shareholder trust in the involved
industry, has provided strong incentives for further research and development of new genetically mod-
ified plant varieties. Considering, however, the high financial stakes involved, concerns are raised over the
influence that conflicts of interest may place upon articles published in peer-reviewed journals that
report on health risks or nutritional value of genetically modified food products. In a study involving
94 articles selected through objective criteria, it was found that the existence of either financial or pro-
fessional conflict of interest was associated to study outcomes that cast genetically modified products in a
favorable light (p = 0.005). While financial conflict of interest alone did not correlate with research results
(p = 0.631), a strong association was found between author affiliation to industry (professional conflict of
interest) and study outcome (p < 0.001). We discuss these results by comparing them to similar studies
on conflicts of interest in other areas, such as biomedical sciences, and hypothesize on dynamics that may
help explain such connections.Introduction
The research and development of genetically modified organ-
isms (GMOs) in agriculture is a relatively recent field in applied
biotechnology research, as the first commercial sowing of a genet-
ically modified (GM) crop took place as recently as 1994. However,
worldwide GM crop acreage has been expanding mostly at two
digit speed totaling 134 million hectares in 2009 (James, 2009),
turning genetic engineering into a global industry worth $10.5 bil-
lion in the same year and expected to grow over an estimated $11
billion by 2011 (James, 2009). So far the majority of GM crops have
been destined for the production of animal feed, but food products
(such as vegetable oils), textiles and biofuels are also common end
products (GMO Compass, 2008). Despite such clear successes GM
crops have also been plagued by consumer rejection, especially
in the European Union (Gaskell et al., 2006).
In its 2008 annual report, Monsanto, the current main global
seller of GM seeds (Lotter, 2008a), stated that this resistance andlow market acceptance is a current risk factor that can undermine
profit rates (Monsanto Company, 2008). While the discourse of
opponents to GM crops in scientific and public communities
extend over a whole range of environmental (Benbrook, 2009;
Lövei and Arpaia, 2005), socioeconomic (Hubbard, 2009), health
(Domingo, 2007; Then and Potthof, 2009) and ethical arguments
(Jensen and Sandoe, 2002), many of these critical discourses con-
verge at the point where the role of science in assessing risks
and impacts is being discussed (Levidow et al., 2005; Myhr and
Traavik, 2003).
In recent years, research institutions have become increasingly
dependent on private funding (Etzkowitz, 2005; Welsh and Glenna,
2007). According to Lotter (2008b) this trend has oriented science
towards a new direction where ‘university research is harnessed to
promote the emergence of a knowledge economy’. It is a model where
some see science as having become ‘embedded in commercial possi-
bility’ (Slaughter and Leslie, 1997). This observed close relationship
between scientific research and industry has led to concerns over
the possible influence of financial conflicts of interests (COIs) in
the design and outcomes of studies investigating human and
animal health risks or nutritional value of GM products (Lotter,
2008b; Myhr and Traavik, 2003). Considering the controversy that
surrounds GMOs, studies are closely watched on both sides. On one
hand, studies showing absence of health risks or demonstrating
nutritional equivalence serve to justify commercialization by com-
panies and authorizations by decision-makers. On the other hand,
studies indicating health or environmental risks have been used by
environmental NGOs to criticize positions favorable to GMO
(Friends of the Earth, 2005; Sample, 2010).
Over the last decades COIs have regularly been the subject of li-
vely debate within the scientific community. Especially in connec-
tion with biomedical sciences, scientists (Kassirer, 2009; Krimsky
and Rothenberg, 1998; Resnik, 2009), journalists (Van Kolfschooten,
2002) and journal editors (Drazen and Curfman, 2002; Smith,
1998) have raised concerns over the integrity of industry sup-
ported research and the need for full disclosure of such information
to readers of scientific articles.
Over time, associations have repeatedly been observed between
study outcomes favoring the industry’s point of view and industry
sponsorship, suggesting a publication bias generated through the
presence of COIs (Ahmer et al., 2005; Als-Nielsen, 2003; Bekelman
et al., 2003; Bhandari et al., 2004; Kjaergard and Als-Nielsen, 2002;
Lexchin et al., 2003). The influence of entanglements of scientists
with industry has also been revealed in other research areas.
Examples include studies on the health effects of smoking
(Diethelm et al., 2005; Muggli et al., 2003) and research in nutri-
tional sciences (Lesser et al., 2007).
The hypothesis of this study is that there exists no relation be-
tween COI and study outcome. Or in other words, COI does not im-
ply actual behavior. But COI does represent an arguable risk that
may draw scientists away from objective study design and obser-
vation (Horton, 1997; Lo, 2009; Smith, 1994). The main question
in this study is whether COIs, through direct industry funding
(financial COI) or through professional affiliations (professional
COI), exert a detectable influence on study outcome for articles
that report on health risks and nutritional value of GM crop derived
foods. Currently no systematized data is available that would pro-
vide clear insights into a topic which has been the subject of a
highly polarized debate for several years.Methodology
The methodology used is from Lesser et al. (2007), a study that
investigated financial COIs within nutrition research, adapted to
the GM topic in terms of article inclusion criteria and expanded
to include professional affiliations. These changes justify a full
length description of the methodology.
Through a set of objective criteria, a sample of articles was gen-
erated. Two independent co-investigators classified the conclu-
sions of each article as generally ‘‘favorable’’, ‘‘unfavorable’’ or
‘‘neutral’’. A third independent co-investigator classified for each
article sponsorship, author affiliation and COI. None of the co-
investigators had any prior knowledge of the classification
produced by their peers and had access only to the article sections
relevant to their task. Finally, the relationship between conclusion
type and sponsors was tested through the application of appropri-
ate statistical methods.Article selection
Articles were initially selected through a series of searches in
the Medline (National Library of Medicine, US) and Web of
Science (ISI Web of Knowledge, Thomson Scientific) bibliographic
databases. Key terms were selected based on commonly used arti-
cle keywords within the scientific literature. Search terms were
composed based on combinations of three key terms. The total
number of search strings was defined by the total amount of pos-sible combinations between the items of three categories of key
terms related to: ‘effects’ (14 key terms), ‘terminology’ (three key
terms) and ‘product purpose’ (two key terms). The first category
contained the following key terms: ‘toxicity’, ‘health effects’, ‘ad-
verse effects’, ‘toxic effects’, ‘dietary effects’, ‘biological effects’,
‘safety’, ‘safety assessment’, ‘safety risks’, ‘evaluation of safety’,
‘health safety’, ‘nutritional value’, ‘effect of feeding’, and ‘feeding
value’. The second category included ‘GM’, ‘genetically modified’
and ‘transgenic’. The third category contained the key terms ‘food’
and ‘feed’. Examples of search strings are ‘health effects of GM
food’, or ‘nutritive value of genetically modified feed’. All possible
combinations totaled 84 search strings. Each search string was ap-
plied to both the Medline and Web of Science databases, resulting
in 168 searches. Afterwards an automatic filter produced a list of
all references occurring in any of the outcome listings.
Articles were further selected through manual review of title
and abstract by applying the following criteria:
 The topic of the article relates to a GM plant as a food or feed
product or as an ingredient of a food or feed product.
 The study involved or considered consumption of the GMO
product by animals or humans with the intention of measuring
a biological response or involved data collection on participants
or from an uncontrolled or natural environment without the
intervention of the investigator.
 At least one endpoint relates directly to health, disease, or a dis-
ease marker in animals or humans or to the nutritional value of
the GMO product under research.
 The article was published between January 1980 and February
2009 (inclusive).
 The article was written in English.
The following step consisted in collecting the full text of the
articles. In those cases where it was not available on the Internet
or through the Portuguese Catholic University’s full text on line
library services, the lead author was contacted. If there was no
response or the request was denied, the article was excluded.
One co-investigator received a document with article extracts
containing only the funding source declaration for each article,
author affiliations and the name of the GMO product under study.
Two other co-investigators had the parallel task of confirming the
inclusion of articles based on the initial selection criteria and clas-
sifying each article’s conclusions according to outcome based on
the abstract, the discussion and conclusion sections of each article.
Classification by funding source and author affiliation
The co-investigator applied his own knowledge or generally
available information on the Internet, to characterize each sponsor
as
 Industry – including corporations or organizations that repre-
sent corporations.
 Industry associated – including organizations or government
agencies that work with industry to promote consumption of
specific foods or the use of specific feeds.
 Non-industry – including governmental agencies with no
industry associations, universities, and independent founda-
tions, philanthropies, and other non-profit organizations.
 Unknown – if information about the sponsor could not be
retrieved.
And classified the affiliation of each author as:
 Academic – including affiliations to universities.
 Non-governmental - including affiliations to independent foun-
dations, philanthropies, and other non-profit organizations.
 Governmental – including affiliations to government agencies
or structures.
 Industry – including affiliations to corporations or organizations
tied to corporations.
 Unknown – if the author’s affiliation could not be identified.
Overall funding source could then be classified for each article as
 All industry – if all financial sponsors were classified as
industry.
 No industry – if all financial sponsors were classified as non-
industry.
 Mixed – if any financial sponsor was classified as industry asso-
ciated, or if the article had financial sponsors that were classi-
fied into more than one category including at least one
sponsor classified as industry.
 Unknown – If all financial sponsors were classified as unknown.
 Undeclared – If no financial sponsors were declared in the
article.
And the author affiliation was further characterized as:
 Affiliation with industry – when at least one of the authors is
affiliated with industry.
 No affiliation with industry – when none of the authors are affil-
iated with industry.
 Undetermined – when not all author affiliations could be iden-
tified and the ones identified are not industry affiliated.
The relationship between sponsor or authors and the product
under investigation was characterized by the co-investigator as
follows:
 Professional COI – if a positive finding appears to be in the com-
mercial interest of a company to which at least one of the
authors is affiliated.
 Funding COI – if a positive finding appears to be in the commer-
cial interest of at least one sponsor classified as industry.
Financing from industry associated entities was not included in
this classification because they represent a heterogeneous category
of where it is difficult to determine the real weight of industry
funding.
Combining the information obtained through previous classifi-
cations, each article could be classified as:
 COI – if COI through sponsorship or author affiliation is present.
 Undetermined – if financial sponsorship was classified as unde-
clared or unknown while no professional COI was identified, or
if minimum one author affiliation was classified as unknown
while no financial conflict was identified.
 No COI – if none of the authors in the article was affiliated to an
entity with a commercial interest in the product under investi-
gation and no sponsors had such commercial interest.
Classification by conclusion type
Articles were divided between those in which the conclusions
were favorable to the interests of the GMO patent holder, and those
that were unfavorable. A third, neutral category was foreseen to in-
clude articles where the outcome was inconclusive.
Articles were classified on the basis both of the general tone of
the author’s discourse and formal conclusions. Acknowledging that
a classification partially based on the tone of discourse does leave
room for subjective interpretation, two co-investigators with dif-
ferent backgrounds were co-opted to carry out the same task inde-
pendently and as such help neutralize any interference personal
bias may bring into the classification.Each article was classified based on the following criteria:
1. Favorable – If the co-investigator finds that no statement were
made that cast the product in a negative light and, at the same
time, the conclusions suggest one or more of the following:
(a) Beneficial health effects.
(b) Increased nutritional value.
(c) Absence of adverse health effects.
(d) Equivalence in nutritional value between the GM product
and the non-GM reference line, if the GM product was not
developed with the aim to increase nutritional value.
2. Unfavorable – If the co-investigator finds that no statements
were made that cast the product in a positive light and, at the
same time the conclusions suggest one or more of the
following:
(a) Absence of expected beneficial health effects.
(b) Adverse health effects.
(c) Lower nutritional value of the GM product when compared
to the non-GM reference line.
(d) Equal nutritional value of the GM product, when compared
to the non-GM reference line, if the GM product was devel-
oped with the aim to increase nutritional value.
3. Neutral – If the co-investigator finds the study is inconclusive or
criteria for a favorable or unfavorable classification were not
met.
Finally, the two co-investigators exchanged classification data
An article was excluded if no consensus was reached on assigned
categories.Statistical analysis
The Fisher Exact Test was applied in order to test the associa-
tions between funding source, author affiliation and conclusion
type (Zar, 1998). This statistical significance test is based on a con-
tingency table in which the observed behavior in a specific situa-
tion is compared with a hypothetical distribution in which no
COI is observed (null hypothesis). P-values were calculated as the
sum of the exact p-value of the observed distribution and any dis-
tribution more extreme than the one observed. The 5% (p < 0.05)
probability level was the threshold used for statistical significance.
Since this research focuses on contrasts between favorable ver-
sus unfavorable studies as regards the GM product under study,
the neutral category articles were left out of the analysis. A conser-
vative approach also led to the exclusion of the ‘mixed’ funding
class, as it represents a heterogeneous group of studies where it
is difficult to differentiate between industry and other funding
sources. Finally, articles where either the presence or absence of
a COI could not be confirmed were also excluded (articles classified
as undetermined).Results
Searches in the Medline and Web of Science databases resulted
in 3626 unique references (after having filtered out duplicates). All
3626 references could be found in a specific minimum combina-
tion of 51 search strings. The remaining 117 searches only pro-
duced duplicates.
Through the manual review of abstract and the title, 120 articles
were selected. Of all but four articles the full text could be retrieved
through the university library. One author did not respond to our
request, two others could not be reached and the fourth study
proved only to be an abstract of a poster presentation by the
author. Furthermore, 12 full texts were not in English, which
reduced the total number of articles to 104. After co-investigator
review, six more articles were left out based on the consensus that
they did not respond to the initial selection criteria. Another four
articles were left out of the statistical analysis as a consensus could
not be reached regarding their conclusion classification. This re-
sulted in a sample of 94 articles accepted for statistical analysis.
Figs. 1 and 2 present detailed information on this sample. In
Fig. 1, the distribution of articles according to publication year
shows that, although inclusion of articles from 1980 onwards
was allowed, no articles were detected before 1996. Fig. 2 provides
information regarding the nature of the included studies. It shows
that the sample had a close to equal representation of studies
investigating GMO products destined for either food or feed (38
and 36), with a smaller proportion of studies considering products
for both human or animal consumption (20). As for distribution of
























Fig. 1. Publication year of articles (n = 94). No articles published before 1996 were
present in the population. Only articles published until the end of February 2009
were included.






































Fig. 2. Distribution of articles according to product purpose, study objective or study t
product, B the distribution according to study objective and C according to study type.on health risks and a smaller group of 28 studies combined conclu-
sions on both nutritional value and health risks. Finally, Fig. 2
shows that a majority of studies were interventional studies (66),
meaning that they considered GM product consumption by ani-
mals or humans with the intention of measuring a biological re-
sponse. There were 28 studies on compositional analysis or
simulations.
The classification of the articles based on the co-investigator
analysis is presented in Table 1. From the 94 articles selected, 80
(85%) were identified as containing a favorable outcome, 12
(13%) were classified as unfavorable and two (2%) as neutral. Fund-
ing was declared in 45 articles (48%). Thirty-six studies (38%) re-
ceived funding from non-industry related sources, two (2%) from
mixed sources and seven (8%) from industry or industry related
sources. Out of these seven articles, six were classified as contain-
ing a financial COI.
As regards affiliation, in 41 articles (44%), at least one of the















ype (n = 94). A shows the article distribution according to the purpose of the GMO
Table 1
Classification of articles by the co-investigators (n = 94). F: Favorable; U: Unfavorable;
N: Neutral.
F U N Total
All articles – 80 12 2 94
Funding source All industry 6 1 0 7
No industry 26 8 2 36
Mixed 2 0 0 2
Unknown 0 0 0 0
Undeclared 46 3 0 49
Financial conflict of interest 5 1 0 6
Author affiliation to industry Yes 41 0 0 41
No 39 12 2 53
Unknown 0 0 0 0
Professional conflict of interest – 41 0 0 41
Conflict of interest (financial and/or
professional)
Yes 43 1 0 44
No 27 8 2 37
Undetermined 10 3 0 13
Table 2
Relation between article conclusion and conflict of interest. Exact p is the statistical
significance of the Fischer Exact Test. In the analysis of COI, only those articles were
included where certainty could be obtained that a COI was either present or absent.
Conflict of interest (COI) Conclusion Exact p
Favorable Unfavorable
Financial COI
Yes 5 1 0.631
No 29 8
Professional COI
Yes 41 0 <0.001
No 39 12
COI (financial and/or professional)
Yes 43 1 0.005
No 27 8
Declaration of funding
Declared 34 9 0.036
Undeclared 46 3
Table 3
Relation between author affiliation and article declaration of funding or funding
source. Exact p is the statistical significance of the Fischer Exact Test.
Article funding At least one another of industry Exact p
Yes No
Declaration of funding
Declared 7 36 <0.001
undeclared 36 13
Funding source
All industry 5 2 <0.001
No industry 2 34affiliation was attributed to any of the remaining articles. For all
these articles a COI was identified through author affiliation to
the industry with a vested commercial interest in the product un-
der research. Combining all information it was possible to deter-
mine that, globally, 44 articles, or 47%, contained either a
financial or professional COI or both. In 37 articles (39%) no COI
was detected, whereas in 13 cases (14%) it could not be determined
with certainty whether a COI was in fact absent or went unde-
tected due to lack of information available on financial sponsorship
or author affiliation.
Regarding financial COI, no association was observed between
the presence of such conflict and article outcome (p = 0.631)
(Table 2). A relationship was found between absence of declaration
of funding and a favorable outcome (p = 0.036) (Table 2). Further-
more, there was a strong connection between undeclared funding
and the presence of one or more authors affiliated to industry
(p < 0.001) (Table 3). Author affiliation to industry was also
strongly related to funding received from an industry source
(p < 0.001) (Table 3). Professional COI was significantly related
with article conclusion (p < 0.001) (Table 2). Finally, a joint analysis
of both data on funding and professional COI revealed that the
presence of COI was significantly related to favorable outcome
(p = 0.005) (Table 2).Discussion
The main finding of our study is that, based on the dataset avail-
able, articles where a COI was identified show a tendency to pro-
duce outcomes favorable to the associated commercial interests.
These results support the overall view that all affiliations should
be clearly acknowledged in scientific publications on the risk anal-
ysis of GM food or feed products, as the existence of such conflicts
of interest is somehow interfering with study outcomes. Due to alack of comparable studies in the genetic engineering area, the
present discussion reflects instead upon publications with similar
approaches conducted for other scientific subjects.
Despite this overall significant result, the data used did not
show a connection between funding source and article outcome.
This seems to contradict a range of evidence demonstrating the
influence that financial conflicts of interest have in other science
areas, especially in biomedical (Lo, 2009) but also in nutritional sci-
ences (Lesser et al., 2007). However, since funding information was
scant, most of the articles had to be excluded from this specific
analysis which could have affected its statistical power. It must
be noted that articles without declaration of funding tend to relate
to a favorable outcome, meaning this category does not represent a
neutral group of articles even though it was conservatively ex-
cluded from the analysis.
On the other hand, a strong relationship was found between
favorable outcome and professional COI. Krimsky et al. (1996)
had already documented the widespread presence of professional
COIs among university based authors through patent ownership,
a function within or holding shares of a biotechnology company.
Within the nutritional sciences Nestle (2007) commented that
relations through financial sponsorship and project partnerships
between academics and industry are rather the rule than the
exception. While professional entanglements with industry or per-
sonal commercial interests and possible publication bias have in
general been researched less than influence of direct funding, the
existence of an influence of such relations has been observed in
biomedical sciences by Friedman and Richter (2004). Also, in
2001, several editors of main medical journals expressed their con-
cerns over industry relations which included professional affilia-
tions. In particular they showed strong opposition against
‘‘contractual agreements that deny investigators the right to examine
the data independently or to submit a manuscript for publication
without first obtaining the consent of the sponsor’’ (Davidoff et al.,
2001). While medical journals have over the years been imple-
menting a number of changes in their disclosure policies to better
deal with COIs (Smith, 1998), recent work still shows the issues
have yet to be solved satisfactorily (Jagsi et al., 2009; Lo, 2009;
Wingate, 2009).
An echo of the above cited editorial sounded in a news feature
in Nature in October 2009, where contractual agreements, publica-
tion restrictions and other dependencies that disturb scientific
integrity were presented as common practice in research on risks
analysis of GM plants (Waltz, 2009). In fact, would-be independent
researchers of GM plants’ potential impacts are even more re-
stricted to carry out their research because of technology agree-
ments that effectively allow a company to prohibit any research
on their product without its explicit authorization even after it
has been approved and marketed. In comparison, patents of phar-
maceutical products do not reach that far in the sense that they do
not prevent any investigation on their performance or impact.
It should be emphasized that, according to the present results,
articles where at least one of the authors is affiliated to industry
are strongly linked to absence of funding declaration. In fact, out
of 41 articles where an industry affiliated author was present, only
seven declared funding. The ratio is opposite in the cases where no
author was observed to be affiliated to industry. Considering that
in all those 41 articles a professional conflict was observed explains
why the majority of articles were included into the combined anal-
ysis of professional and funding COI. In this analysis only 15 arti-
cles were excluded as it could not be determined whether a
financial COI was either absent or present even though no profes-
sional COI was observed (13) or they were classified as neutral
(two).
Current data do not provide sufficient insight into the underly-
ing dynamics that lead to this particular result, which renders
interpretation speculative. One possibility is that studies with ac-
tive industry participation choose to publish in journals where
there are no strict requirements over funding disclosure in order
not to reveal funding sources. Very few studies with declared fund-
ing received funding from industry only. Additionally, the absolute
majority of studies with non-industry funding had no involvement
of industry affiliated authors. However, it is unlikely that the pro-
portion of non-industry versus industry funding is representative
for research in GM crops, considering the high involvement of
industry in biotechnology research (Lotter, 2008b).
Since the data available make no mention of contractual agree-
ments or publication restrictions, other causes, as suggested by
Lesser et al. (2007) may explain the observed association. Industry
may tend to choose to be involved only in such research that is
likely to cast their product in favorable light, or researchers, under
certain conditions, may design studies and draw conclusions that
respond to the financial interests of their industrial sponsors or
employers.
Financial COIs are also not the only type of personal conflicts
that researchers may face (Bekelman et al., 2003; Hirsch, 2009).
Career considerations, long standing personal scientific viewpoints,
or value-based opinions over the role of science in society and faith
in technology as a useful tool for solving global problems, may
influence author perceptions and study outcomes.
We recognize that similar dynamics may apply to researchers
and studies funded by other sources than industry, such as govern-
ment agencies or civil society organizations, since those entities
may have a preference towards funding studies or researchers
serving their political agendas. In the same line, Ravetz (2004) con-
siders that modern science in general is set ‘by the external interests
that supply funds’ and scientists are influenced by values. While
interests and personal values are not the same, they may coincide.
Kvakkestad et al. (2007) for example found that the perspectives of
scientists in regard to the deliberate release of GMOs are related to
the nature of their employer.
In order to further shed light on the influence of financial COIs it
will be necessary to see how the data presented here associates
with journal titles and their respective disclosure policies. Consid-
ering the high number of studies with no declared funding it
should also prove useful to investigate financial sources. Finally,
it will be interesting to also analyze environmental risk studies
or to include risk analysis studies of other (non-GMO) food prod-
ucts, which would allow for a comparison between different types
of studies.Conclusion
The presence of COI in scientific research does not imply actual
behavior of study authors. But it does present a risk that the study
outcome may be improperly influenced. This study has focused on
how commercial interests may interfere with outcomes of risk and
nutrition analysis studies of products derived from GM plants. This
is a choice justified by the high financial stakes involved in the
development of such products and the increasing weight of private
funding in research in recent years.
Through statistical analysis of a selected population of studies
in the described area, it could be shown that a combined analysis
of COIs through professional affiliations or direct research funding
are likely to influence the final outcome of such studies in the com-
mercial interest of the involved industry. Our results partially con-
firm those observed in biomedical sciences, tobacco, alcohol and
nutrition research.
Various hypothesis could be identified that may explain the ob-
served association between study outcome and presence of finan-
cial COI: publication restrictions imposed by industry funders;contractual agreements of authors with industry; industry bias
favoring friendly research; and researchers that are sensitive to
the financial interests of their industrial sponsors or employers.
Apart from the observed relations, it was considered that types
of funding other than industry, such as governments and NGOs
may also condition investigation. Additionally, values held by sci-
entists may influence research outcomes as well.
Our data reinforce the need to that all affiliations whether
financial or professional should be openly declared in scientific
publications. In situations where health risk assessments or nutri-
tional evaluation studies of GM products serve to inform decision-
makers, procedures could be developed to minimize the risk of
decisions being taken based on study outcomes that have been
influenced by conflicts of interest. This may best be achieved by
giving preference towards peer-reviewed studies where no COI
can be observed.Acknowledgement
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